- Home
- SONN vs RDHL Comparison
SONN vs RDHL Comparison
Compare SONN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- RDHL
- Stock Information
- Founded
- SONN N/A
- RDHL 2009
- Country
- SONN United States
- RDHL Israel
- Employees
- SONN N/A
- RDHL N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- RDHL Health Care
- Exchange
- SONN Nasdaq
- RDHL Nasdaq
- Market Cap
- SONN 3.8M
- RDHL 3.8M
- IPO Year
- SONN N/A
- RDHL N/A
- Fundamental
- Price
- SONN $1.17
- RDHL $1.86
- Analyst Decision
- SONN Strong Buy
- RDHL
- Analyst Count
- SONN 1
- RDHL 0
- Target Price
- SONN $20.00
- RDHL N/A
- AVG Volume (30 Days)
- SONN 35.1K
- RDHL 217.8K
- Earning Date
- SONN 05-13-2025
- RDHL 04-10-2025
- Dividend Yield
- SONN N/A
- RDHL N/A
- EPS Growth
- SONN N/A
- RDHL N/A
- EPS
- SONN N/A
- RDHL N/A
- Revenue
- SONN $1,000,000.00
- RDHL $8,042,999.00
- Revenue This Year
- SONN $5,376.22
- RDHL $381.91
- Revenue Next Year
- SONN N/A
- RDHL N/A
- P/E Ratio
- SONN N/A
- RDHL N/A
- Revenue Growth
- SONN 978.39
- RDHL 23.17
- 52 Week Low
- SONN $1.08
- RDHL $1.71
- 52 Week High
- SONN $16.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- SONN 41.23
- RDHL 41.17
- Support Level
- SONN $1.08
- RDHL $1.73
- Resistance Level
- SONN $1.21
- RDHL $1.93
- Average True Range (ATR)
- SONN 0.07
- RDHL 0.08
- MACD
- SONN -0.01
- RDHL 0.02
- Stochastic Oscillator
- SONN 29.03
- RDHL 65.00
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.